ArticleMycobiology2010
In Vitro Antifungal Activity of Equol against Candida albicans.
Article in Mycobiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Antifungal Activity of a Postbiotic Cell-free Supernatant of Lactiplantibacillus plantarum from Pulicaria jaubertii against Aspergillus fumigatus and Candida albicans.BMC complementary medicine and therapies · 2026Article
- Alginate-Polymethacrylate Hybrid Microparticles as Multi-Unit Enteric Drug Carriers for Posaconazole.Pharmaceutics · 2026Article
- Antifungal efficacy of Azadirachta indica and Ficus benghalensis extracts against azole resistant Candida albicans on denture resin.Scientific reports · 2025Article
- The Antifungal Effects of Equol AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Antifungal activities of Equol againstVirulence · 2024Article
- Biological Activity of Biosynthesized Silver Nanoaggregates Prepared from the Aqueous Extract ofNanomaterials (Basel, Switzerland) · 2023Article
- The Impact of Hypromellose on Pharmaceutical Properties of Alginate Microparticles as Novel Drug Carriers for Posaconazole.International journal of molecular sciences · 2023Article
- Bioactivity Screening and Chemical Characterization of Biocompound from EndophyticMicroorganisms · 2023Article
- The Spray-Dried Alginate/Gelatin Microparticles with Luliconazole as Mucoadhesive Drug Delivery System.Materials (Basel, Switzerland) · 2023Article
- Anti-bacterial and Anti-biofilm Effects of Equol onIndian journal of microbiology · 2022Article
- Geographic Variability of Berry Phytochemicals with Antioxidant and Antimicrobial Properties.Molecules (Basel, Switzerland) · 2022Article
- Does the Freeze-Thaw Technique Affect the Properties of the Alginate/Chitosan Glutamate Gels with Posaconazole as a Model Antifungal Drug?International journal of molecular sciences · 2022Article
- Synergistic Activity of Equol and Meropenem against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Partridge and embryonated partridge egg as new preclinical models for candidiasis.Scientific reports · 2021Article
- Anti-Fungal Efficacy and Mechanisms of Flavonoids.Antibiotics (Basel, Switzerland) · 2020Review
- Sida hermaphrodita seeds as the source of anti - Candida albicans activity.Scientific reports · 2019Article
- Equol, a Clinically Important Metabolite, Inhibits the Development and Pathogenicity of Magnaporthe oryzae, the Causal Agent of Rice Blast Disease.Molecules (Basel, Switzerland) · 2017Article
- Methylene Blue-Loaded Dissolving Microneedles: Potential Use in Photodynamic Antimicrobial Chemotherapy of Infected Wounds.Pharmaceutics · 2015Article
- Propolis Is an Efficient Fungicide and Inhibitor of Biofilm Production by Vaginal Candida albicans.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Synergistic antifungal effect of glabridin and fluconazole.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we demonstrate that equol has fungicidal activities against Candida albicans. The minimum inhibitory and minimum fungicidal concentrations of equol against C. albicans were 516 and 1,032 µM, respectively. Two separate viability assays found that equol changed the integrity of the C. albicans cell membrane, possibly by formation of membrane lesions. Scanning electron microscopy demonstrated ultrastructural changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.